美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Hemab Therapeutics Holdings, Inc.

34.00

+16.0088.89%

盤後：33.10-0.9000-2.65%19:59 EDT

成交量：411.35萬

成交額：1.29億

市值：13.33億

市盈率：- -

高：36.61

開：27.00

低：27.00

收：18.00

52周最高：36.61

52周最低：27.00

股本：3,920.76萬

流通股本：1,176.47萬

量比：- -

換手率：34.96%

股息：- -

股息率：- -

淨資產收益率：-46.99%

總資產收益率：-30.11%

市淨率：-7.55

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Hemab Therapeutics Holdings, Inc.

交易所：

NASDAQ

成立時間：

2020

員工人數：

59

公司地址：

101 Main Street,Suite 1220,Cambridge,Massachusetts,United States

官網：

http://www.hemab.com

郵編：

02142

電話：

傳真：

- -

簡介：

Hemab Therapeutics Holdings, Inc.於2026年2月12日根據特拉華州法律註冊成立。Hemab Therapeutics是一家臨床階段的生物技術公司，致力於開發革新血液凝固障礙治療的療法，以幫助維持生命並增強人類的抵抗力。公司的使命是通過發現、開發和商業化創新療法，為全球患有嚴重出血和血栓性疾病的患者打造領先的凝血領域公司。這些疾病包括格氏血小板無力症、VII因子缺乏症、血管性血友病以及其他可能造成終身沉重負擔的異常出血性疾病。公司的主要候選藥物sutacimig (HMB-001) 是一種雙特異性抗體，目前正在進行一項針對格氏血小板無力症預防性治療的I/II期臨床試驗和一項針對VII因子缺乏症預防性治療的II期臨床試驗。

董事

名稱

職位

Benny Sorensen

Chief Executive Officer and Director and President

Akshay Vaishnaw

Independent Director

John Maraganore

Chair of the Board and Independent Director

Laura Tadvalkar

Independent Director

Linda Bain

Independent Director

股東

名稱

職位

Benny Sorensen

Chief Executive Officer and Director and President

Ananthram Murthy

Chief Operating Officer

Mads Behrndt

Chief Financial Officer and General Manager

Catherine Madigan

Chief Medical Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/COAG/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COAG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":34,"timestamp":1777665600000,"preClose":18,"halted":0,"volume":4113516,"hourTrading":{"tag":"盘后","latestPrice":33.1,"preClose":34,"latestTime":"19:59 EDT","volume":24517,"amount":807452.3188,"timestamp":1777679985243,"change":-0.9,"changeRate":-0.026471,"amplitude":0.054412},"delay":0,"changeRate":0.8888888888888888,"floatShares":11764706,"shares":39207616,"eps":0,"marketStatus":"休市中","change":16,"latestTime":"05-01 16:00:00 EDT","open":27,"high":36.61,"low":27,"amount":128926048.828896,"amplitude":0.533889,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":7,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":18,"postHourTrading":{"tag":"盘后","latestPrice":33.1,"preClose":34,"latestTime":"19:59 EDT","volume":24517,"amount":807452.3188,"timestamp":1777679985243,"change":-0.9,"changeRate":-0.026471,"amplitude":0.054412},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","floatShares":11764706,"roa":"-30.11%","roe":"-46.99%","lyrEps":0,"shares":39207616,"dividePrice":0,"high":36.61,"amplitude":0.533889,"preClose":18,"low":27,"week52Low":27,"pbRate":"-7.55","week52High":36.61,"institutionHeld":0,"latestPrice":34,"eps":0,"divideRate":0,"volume":4113516,"delay":0,"ttmEps":0,"open":27,"prevYearClose":18,"prevWeekClose":18,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":18,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COAG\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COAG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"COAG\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/COAG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"COAG","date":"2026-05-01","current":-11.042152,"percent":1,"low":-11.042152,"twenty":-11.042152,"median":-11.042152,"eighty":-11.042152,"high":-11.042152,"avg":-11.042152,"sd":0,"marketCap":705737088},"quantilePoints":[{"date":"2026-05-01","current":-11.042152,"twenty":-11.042152,"median":-11.042152,"eighty":-11.042152,"marketCap":705737088}],"updateTime":1777819303442},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1994300807,"yearFounded":2020,"employeeNum":59,"address":"101 Main Street,Suite 1220,Cambridge,Massachusetts,United States","zipCode":"02142","officePhone":"(617) 553-3952","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.hemab.com","stockEarnings":[{"period":"1week","weight":0.8889},{"period":"ytd","weight":0.8889}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Hemab Therapeutics Holdings, Inc.於2026年2月12日根據特拉華州法律註冊成立。Hemab Therapeutics是一家臨床階段的生物技術公司，致力於開發革新血液凝固障礙治療的療法，以幫助維持生命並增強人類的抵抗力。公司的使命是通過發現、開發和商業化創新療法，為全球患有嚴重出血和血栓性疾病的患者打造領先的凝血領域公司。這些疾病包括格氏血小板無力症、VII因子缺乏症、血管性血友病以及其他可能造成終身沉重負擔的異常出血性疾病。公司的主要候選藥物sutacimig (HMB-001) 是一種雙特異性抗體，目前正在進行一項針對格氏血小板無力症預防性治療的I/II期臨床試驗和一項針對VII因子缺乏症預防性治療的II期臨床試驗。","exchange":"NASDAQ","name":"Hemab Therapeutics Holdings, Inc.","nameEN":"Hemab Therapeutics Holdings, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"COAG\",market:\"US\",,,undefined,":{"directors":[{"name":"Benny Sorensen","position":"Chief Executive Officer and Director and President"},{"name":"Akshay Vaishnaw","position":"Independent Director"},{"name":"John Maraganore","position":"Chair of the Board and Independent Director"},{"name":"Laura Tadvalkar","position":"Independent Director"},{"name":"Linda Bain","position":"Independent Director"}],"executives":[{"name":"Benny Sorensen","position":"Chief Executive Officer and Director and President"},{"name":"Ananthram Murthy","position":"Chief Operating Officer"},{"name":"Mads Behrndt","position":"Chief Financial Officer and General Manager"},{"name":"Catherine Madigan","position":"Chief Medical Officer"}]}}}